Fertility future with testicular cryopreservation

Fertility preservation is now a reality for male pediatric and adolescent/young adult (AYA) patients with cancer or blood disorders.

The Hyundai Cancer Institute at CHOC Children’s is a center of excellence and the only program on the West Coast offering testicular preservation for prepubertal patients unable to bank sperm. Testicular tissue is biopsied and preserved in liquid nitrogen.

“Recent research indicates these biopsies contain stem cells, leading to the possibility of generating sperm in the future,” said Dr. Carol Lin, a pediatric oncologist at the CHOC Hyundai Cancer Institute.

Evidence-based research

CHOC participated in an eight-year study alongside U.S. and Israeli institutions to establish a standardized protocol and centralized process to freeze and collect biopsies.

A CHOC Children's pediatric urologist speaks with an adolescent male patient in an exam room

“In total, 189 patients provided samples. A quarter of each sample was used for research and the rest stored for future use. These patients ranged from ages 5 months to 34, with an average age of about 8,” said Lin.

The study discovered that a centralized process and testicular biopsies from multiple sites was a viable option and could accelerate recruitment. Click here to learn more about the study.

Sharing expertise

CHOC is a member of the Oncofertility Consortium, a group of scientists and providers who are committed to fertility preservation in cancer patients. The consortium studies the science of cryopreservation methods, storage of tissue, in vitro follicle growth and communication between patients and doctors, as well as ethical and legal concerns.

Our care and commitment to children has been recognized

CHOC Children’s Hospital was named one of the nation’s best children’s hospitals by U.S. News & World Report in its 2020-21 Best Children’s Hospitals rankings and ranked in the cancer specialty.

Best Children's Hospitals, U.S. News & World Report, Cancer, 2020-21

Learn how CHOC’s pediatric oncology treatments, expertise and support programs preserve childhood for children in Orange County, Calif., and beyond.

Premier CHOC leukemia and immunotherapy conference draws international experts

A premier CHOC Children’s symposium centered around the complex issues facing pediatric leukemia patients drew more than 150 international leaders in the field of children’s leukemia treatment and research. This two-day conference had 33 speakers from various renowned institutions.

Building on the scientific foundation and exchange of information established in the gathering’s five-year history, attendees of the 2018 Society of Young Adult Oncology (SAYAO)/CHOC Children’s Leukemia Symposium shared the latest scientific and clinical advances in acute leukemia, specifically immunotherapy.

CHOC Children’s physician Dr. Van T. Huynh, chaired the symposium and presented her research on asparaginase therapy and silent inactivation.

Titled “From Pediatric to Adult Acute Lymphoblastic Leukemia – The Age of Cellular Therapy,” the Nov. 5 and 6 symposia focused largely on CAR-T cell therapy and new agents for the treatment of acute leukemia. Specific topics included:

  • an update on CAR-T cell products and trials;
  • the future of CD 19, CD22 and NK CAR cell trials;
  • the economics of CAR-T cell therapy;
  • update on leukemia therapy for pediatrics and adolescent and young adults; and
  • supportive care and oncofertility for the leukemia patient.

The symposium drew more than 150 international pediatric leukemia leaders and 33 speakers from various renowned institutions.

The symposium was chaired by CHOC physician Dr. Van T. Huynh, who also presented her research on asparaginase therapy and silent inactivation. CHOC physician Dr. Carol Lin discussed toxicity and management of asparaginase therapy.

Learn more about referring a patient to the Hyundai Cancer Institute at CHOC Children’s.